Proteomic Analyses of Pancreatic Cyst Fluids
Overview
Authors
Affiliations
Objectives: There are currently no diagnostic indicators that are consistently reliable, obtainable, and conclusive for diagnosing and risk-stratifying pancreatic cysts. Proteomic analyses were performed to explore pancreatic cyst fluids to yield effective diagnostic biomarkers.
Methods: We have prospectively recruited 20 research participants and prepared their pancreatic cyst fluids specifically for proteomic analyses. Proteomic approaches applied were as follows: (1) matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry peptidomics with LC/MS/MS (HPLC-tandem mass spectrometry) protein identification; (2) 2-dimensional gel electrophoresis; (3) GeLC/MS/MS (tryptic digestion of proteins fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified by LC/MS/MS).
Results: Sequencing of more than 350 free peptides showed that exopeptidase activities rendered peptidomics of cyst fluids unreliable; protein nicking by proteases in the cyst fluids produced hundreds of protein spots from the major proteins, making 2-dimensional gel proteomics unmanageable; GeLC/MS/MS revealed a panel of potential biomarker proteins that correlated with carcinoembryonic antigen (CEA).
Conclusions: Two homologs of amylase, solubilized molecules of 4 mucins, 4 solubilized CEA-related cell adhesion molecules (CEACAMs), and 4 S100 homologs may be candidate biomarkers to facilitate future pancreatic cyst diagnosis and risk-stratification. This approach required less than 40 microL of cyst fluid per sample, offering the possibility to analyze cysts smaller than 1 cm in diameter.
Iwashita T, Uemura S, Shimizu M J Med Ultrason (2001). 2023; 51(2):219-226.
PMID: 38051460 DOI: 10.1007/s10396-023-01389-6.
The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y, Wang Y, Hoti N, Clark D, Chen S, Zhang H Mass Spectrom Rev. 2021; 42(2):822-843.
PMID: 34766650 PMC: 9095761. DOI: 10.1002/mas.21748.
Application of EUS-based techniques in the evaluation of pancreatic cystic neoplasms.
Sun L, Huang H, Jin Z Endosc Ultrasound. 2021; 10(4):230-240.
PMID: 34213426 PMC: 8411565. DOI: 10.4103/EUS-D-20-00216.
Differences in Expression in Pancreatic Cancers and Pancreatic Cysts in Egypt.
Etekpo A, Alghawalby A, Alghawalby M, Soliman A, Hablas A, Chen B J Carcinog Mutagen. 2021; 9(1).
PMID: 34164227 PMC: 8218782. DOI: 10.4172/2157-2518.1000312.
Do M, Kim H, Shin D, Park J, Kim H, Han Y Cancers (Basel). 2020; 12(9).
PMID: 32842508 PMC: 7565268. DOI: 10.3390/cancers12092383.